Genetic recombination of poly(l-lysine) functionalized apoferritin nanocages that resemble viral capsid nanometer-sized platforms for gene therapy.
Animals
Apoferritins
/ chemistry
Breast Neoplasms
/ genetics
Capsid
/ chemistry
Cell Line, Tumor
Endocytosis
Female
Genetic Therapy
HeLa Cells
Humans
Mice
Nanoparticles
Particle Size
Polylysine
/ genetics
RNA, Small Interfering
/ genetics
Receptors, Transferrin
/ antagonists & inhibitors
Recombination, Genetic
Xenograft Model Antitumor Assays
Journal
Biomaterials science
ISSN: 2047-4849
Titre abrégé: Biomater Sci
Pays: England
ID NLM: 101593571
Informations de publication
Date de publication:
17 Mar 2020
17 Mar 2020
Historique:
pubmed:
6
2
2020
medline:
28
10
2020
entrez:
4
2
2020
Statut:
ppublish
Résumé
Currently, bioengineered apoferritin nanocages with flexible protein shells and functionalized modifications have become an attractive approach for efficient anti-tumor therapy. Here, we modified the N-terminus of H-chain subunits in apoferritin with different amounts of lysine via genetic recombination to obtain a poly(l-lysine) modified H-chain apoferritin (nL-HFn) nanocage for siRNA delivery and gene therapy. To achieve excellent cellular affinity and uptake, the nanocarriers were internalized through transferrin receptor-mediated endocytosis, then escaped from the endosome for cytoplasmic transport. Compared with natural apoferritin, the siRNA-loaded genetic recombination NPs modified with lysine exhibit stronger RNA-interference and antitumor efficiency both in vitro and in 4T1 tumor model mice. Therefore, bioengineered apoferritin nanocages modified with lysine might be a promising platform for nucleic acid drug delivery.
Substances chimiques
RNA, Small Interfering
0
Receptors, Transferrin
0
Polylysine
25104-18-1
Apoferritins
9013-31-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM